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Fatty acid oxidation in myocardium: Effects of parathyroid hormone
and CRF. Fatty acids constitute an important substrate utilized by the
myocardium as a major fuel for energy production; certain data suggest
that oxidation of long chain fatty acids (LCFA) may be impaired in
uremia, and such a derangement could, in part, contribute to the
myocardiopathy of uremia. The latter is associated with secondary
hyperparathyroidism and PTH has been shown to affect myocardial
metabolism. The present study evaluated in rats the effects of four days
administration of PTH and 21 days of chronic renal failure (CRF) with
and without excess PTH on oxidation of s-ketoglutarate, /3-hydroxy-
butyric acid, LCFA and short chain fatty acids (SCFA). PTH impaired
oxidation of a-ketoglutarate, LCFA, SCFA, but not of /3-hydroxy-
butyric acid and reduced the activity of carnitine palmitoyl transferase
(CPT). Inactivation of the PTH abolished its effects. CRF rats with
intact parathyroid glands also had impaired oxidation of LCFA and
CTP activity. Carnitine contents of myocardium were not altered. The
data show that PTH excess in normal rats is associated with impaired
oxidation of LCFA and SCFA, and secondary hyperparathyroidism in
CRF animals impairs oxidation of LCFA. This effect is due to: 1)
reduction in the activity of CPT, a key enzyme for the transport of
LCFA to mitochondrial matrix for p-oxidation; and 2) impairment in
/3-oxidation. The data provide for new and additional pathway through
which excess PTH and CRF can affect myocardial metabolism.
Parathyroid hormone (PTH) exerts a variety of effects on the
heart. The hormone stimulates cyclic AMP production by heart
cells, increases the beating rate and causes death after pro-
longed exposure to it [1]. PTH antagonizes the depressant effect
of propranolol on the contractile force of isolated guinea pig
auricles [2], and Kahot et al [3] described an increase in the
contractile force of heart papillary muscle by PTH. In addition,
treatment of rats with this hormone has been associated with
decreased myocardial energy production, shuttle and utilization
and with a decrease in cardiac output [4].
Several experimental and clinical observations suggest that
the state of secondary hyperparathyroidism of renal failure [5,
6] participates in the pathogenesis of the uremic myocardiop-
athy. It has been found that cardiac lesions predictably oc-
curred in uremic rats and administration of PTH enhanced these
lesions, while parathyroidectomy either inhibited or completely
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prevented their development [7, 8]. Bogin, Massry and Harary
[1] showed that the effect of uremic sera on the chronotropic
property of heart cells is abolished in the absence of PTH.
Additional studies from our laboratory have demonstrated that
chronic renal failure in rats was associated with impaired
myocardial energy production, transfer and utilization, and that
parathyroidectomy corrected many of these abnormalities [9].
Finally, Drueke et al [10] found marked improvement in left
ventricular function after subtotal parathyroidectomy in 22
dialysis patients with secondary hyperparathyroidism, and Mc-
Gonigle et al [11] reported an improvement in left ventricular
performance in dialysis patients after the medical suppression
of parathyroid glands activity.
Fatty acids constitute an important energy source for the
heart under aerobic conditions [12, 131, and the normality of
their oxidation is important for the functional integrity of the
myocytes. Impairment of fatty acid oxidation may be present in
uremia [14], and such an abnormality would provide another
mechanism underlying the myocardiopathy of chronic renal
failure.
Excess PTH in rats with normal renal function [4] and in
those with chronic renal failure [9] impaires oxidation of a-
ketoglutarate by heart mitochondna; it is theoretically possible
that the hormone also affects fatty acid oxidation by these
structures. The present study was undertaken to examine the
effect of PTH and of chronic renal failure with and without
excess PTH on the oxidation of fatty acids by the myocardium.
Methods
The experiments were performed on male Sprague-Dawley
rats weighing 250 to 280 g. The animals were housed in
individual cages and fed normal rat chow (Wayne Research
Animal Diets, Chicago, Illinois, USA) throughout the study.
The diet contained 1.4% calcium, 0.97% phosphorus, and 4.4
IU/g of vitamin D. We previously found that treatment of rats
with PTH for four days produced a significant decrease in
oxygen consumption by heart mitochondria [4].
Therefore, the present study utilized the four day protocol of
PTH treatment. The hormone was dissolved in normal saline.
Two hundred U/day of bovine 1-84 PTH or 200 or 300 U/day of
synthetic 1-34 PTH (Sigma Chemical Co., St. Louis, Missouri,
USA) were given intraperitoneally in two divided doses
(morning and afternoon) for four days. The control animals
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received similar sham injections containing the vehicle (saline)
only. Studies were also performed with 200 U/day of inacti-
vated 1-84 PTH given for four days. The inactivation of 1-84
was done as follows: 10 to 15 zg of PTH was dissolved in 60 d
0.15 N acetic acid, and to this solution 40 d of 30% vollvol H202
were added. The solution was incubated at 37°C for 45 minutes,
and the reaction was terminated by freezing, which was fol-
lowed by lyophilization. On the morning of day 5, the animals
were sacrificed and oxidation of fatty acids, /3-hydroxybutyric
acid and a-ketoglutarate by myocardial mitochondria, the ac-
tivity of carnitine palmitoyl transferase and carnitine content of
heart were examined.
Similar measurements were also done at day 22 of chronic
renal failure in the presence and absence of parathyroid glands.
Parathyroidectomy (PTX) was performed by electrocautery,
and the success of the procedure was ascertained by a decrease
in serum levels of calcium of at least 2 mgldl. Normocalcemia
was restored by allowing the animals free access to drinking
water containing 50 glliter of calcium gluconate. The animals
underwent right partial nephrectomy through a flank incision
seven days after PTX; a week later, a left nephrectomy was
performed. The nephrectomy procedures were also performed
in rats with intact parathyroid glands. Thus, this protocol
provided two groups of animals with chronic renal failure
(CRF): one with intact parathyroid glands (CRF-control) and
the other without parathyroid glands (CRF-PTX). Studies were
also performed in normocalcemic parathyroidectomized rats
with normal function (normal-PTX) and the experiments were
done 22 days after parathyroidectomy.
After animals were sacrificed by decapitation, the hearts
were removed and washed from blood. A small piece of
ventricles was frozen with liquid nitrogen and kept at 70°C for
the measurement of carnitine. The remainder of the ventricles
were used for the isolation of mitochondria according to the
method of Yang, Gieger and Bessman [15]. About 1 g of
myocardium was placed in an ice-cold homogenization media
containing 180 mrvi KCI, 10 mst EDTA disodium with pH
adjusted to 7.4. The tissue was then cut into small pieces, run
through a Harvard tissue press and treated for 30 minutes with
trypsin and then homogenized with a Dounce type homoge-
nizer. A trypsin inhibitor was then added to stop the reaction.
The mixture was homogenized again and then centrifuged for 10
minutes, at 400 g, in a Sorvall RC-5 refrigerated centrifuge
(DuPont Co., Instrument Product Division, Newton Connecti-
cut, USA). The pellet was discarded and the supernatant was
centrifuged at 8000 g for 10 minutes for final isolation of the
mitochondria. The mitochondrial pellet was washed several
times and suspended in media containing 180 mM KC1 and 10
mM Tris HC1, and centrifuged for 10 minutes at 8000 g. The
pellet was suspended in media containing 180 mM KCI, 10 mM
Tris HC1 and 0.5% (wt/vol) dialyzed albumin. The pH of the
media was 7.4. The protein concentration of the pellet was
determined by a modification of the method of Lowry et al [16].
The isolated mitochondria were used for the study of the
oxidation of a-ketoglutarate, /3-hydroxybutyric acid (BHBA)
and long and short chain fatty acids and for the activity of the
carnitine palmitoyl transferase. The substrate oxidation rate
and ADP:0 ratio were determined polarographically by means
of Clark oxygen electrode (Gibson Medical Electronics, Mid-
dleton, Wisconsin, USA), fitted to a plexiglass chamber of 2.0
ml capacity as described originally by Chance and Williams
[17]. The details for the study of a-ketoglutarate oxidation have
been previously reported from our laboratory [4]. The amount
of ADP added each time to the oxygraph chamber was 250
mol. The complete system for BHBA and fatty acid oxidation
contained between 1.0 and 1.5 mg mitochondrial protein added
to 2.0 ml of incubation media containing (in mM): 230 mannitol,
10 Tris HCI, 0.02 EDTA disodium, 5 potassium phosphate, 70
sucrose and 1 malate. The final pH was 7.2 and the temperature
28°C. For the study of the oxidation of BHBA (Sigma Chemical
Co.), about 1.0 to 1.5 mg of mitochondrial protein contained in
100 d and 50 p1 of 16 m of BHBA were present in the
incubation media in the oxygraph chamber. In the studies of the
oxidation of short chain fatty acids (SCFA), the media in the
oxygraph chambers contained about 1.0 to 1.5 mg of mitochon-
drial protein suspended in 120 p1 and 50 p1 of 40 ifiM octanoic
acid (Sigma Chemical Co.). The studies for the evaluation of the
long chain fatty acids (LCFA) oxidation utilized activated fatty
acid palmitoyl CoA (Sigma Chemical Co.). To prepare this fatty
acid for use in the study, 1 mg of palmitoyl CoA was added to
1 ml of 96% ethanol and sonicated for 10 to 15 minutes and then
diluted with 9 ml of distilled water. About 1.0 to 1.5 mg
mitochondrial protein contained in 100 p1 of mitochondnal
solution, 50 p1 of 2 m of LD-carnitine and 30 p1 of 0.1 ms
palmitoyl CoA were added to the incubation chamber. Oxygen
consumption was recorded and results were calculated accord-
ing to Chance and Williams (17) and expressed as nanomoles of
oxygen per milligram of protein per minute.
The activity of carnitine palmitoyl transferase was measured
by the method of Bieber, Abraham and Helmarth [18]. This
enzyme activity is determined by the release of free CoA in the
presence of exogenous L-carnitine, palmitoyl CoA and 5.5'-
dithobis-(2 nitrobenzoate) (DTNB). The free CoA reduces
DTNB giving a yellow color which has a molar absorbance per
centimeter of 13.6 x i03 at 412 nm and at pH 8.0. To eliminate
the effect of endogenous mitochondrial L-carnitine, a parallel
assay is run with excess D-carnitine, which inhibits the reaction
(blank); the activity of the enzyme is then calculated as the
difference between results observed in the presence of L- and
D-carnitine and expressed as nanomoles of CoA per milligram
protein per minute. Carnitine was measured by the methods of
Cederblad and Linstedt [191 and of Borum, York, and Bennett
[20]; non-collagen protein was determined by the methods of
Itzhaki and Gill [21] and Lilienthal et a! [221. The results are
expressed as nmolImg non-collagen protein.
In all studies, blood samples were obtained for the measure-
ments of calcium with atomic absorption spectrophotometer
(Model 505, Perkin Elmer Corporation, Norwalk, Connecticut,
USA) and for inorganic phosphorus and creatinine with an
autoanalyzer (Technicon Corp., Tarrytown, New York, USA).
Data are expressed as mean SE and statistical significance
was evaluated by parametric t-test.
Results
There were no significant differences in the blood levels of
calcium between normal rats (9.6 0.2 mgldl) and those treated
with 200 U/day 1-84 PTH (9.9 0.2 mgldl), 200 U/day of 1-34
PTH (10.0 0.40 mg/dl) or 300 U/day of 1-34 PTH (9.7 0.2
mg/dl). However, blood levels of phosphorus were significantly
lower (P < 0.01) in the rats treated with 1-84 PTH (6.3 0.3 mg/
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Table 1. Effect of 1-84 PTH, inactivated 1-84 PTH, and 1-34 PTH on the oxidation of a-ketoglutarate BHBA and long chain fatty acids by
heart mitochondria, the activity of carnitine palmitoyl transferase, and on carnitine content of the heart
Normal
1-84 PTH
200 U
Inactivated
1-84 PTH
200 U
1-34 PTH
200 U 300 U
Respiratory control ratio 10.9 0.85 11.3 0.7 12.3 0.50 9.8 0.69 10.4 0.98
ADP/O 3.0 0.04 2.9 0.09 2.8 0.5 2.9 0.07 3.0 0.04
Oxygen consumption
nmol 02/mg protein/mm
a-ketoglutarate 184 4.4 141 3,7a 184 4.6 183 3.5 153 34a
/3-hydroxybutyric acid 33 2.0 28 1.2 32 1.95 30 2.3 31 1.6
Palmitoyl Co A 68 2.9 54 2.2a 64 3.1 62 2.5 36 2.6a
Carnitine palmitoyl
transferase
nmolCoA/mgprotein/min 19.6 0.48 13.3 0.59a 19.5 0.63 20.0 1.7 13.2 0.44a
Carnitine content
nmol/mg NCP 9.2 1.40 6.5 1.46 — 9.2 0.77
Data are presented as mean SE of studies in 6 rats
non-collagen protein.
a P < 0.01 vs. normal
except for carnitine content in 1-84 PTH treatment (rats 4). Abbreviation is: NCP,
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Fig. 2. Effects of administration of 200 () and 300(111111) U of 1-34 PTH
to normal () rats on oxygen consumption by their ,nyocardial mito-
chondria utilizing a-ketoglutarate (a-KG), long chain fatty acids (L-
CFA), /3-hydroxybutyric acid (BHBA). Each column represents mean
value and brackets denote 1 SE.
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Fig. 1. Effects of administration of 1-84 PTH (•) or inactivated hor-
mone (U) to normal (Q) rats on oxygen consumption by their myocar-
dial mitochondria utilizing a-ketoglutarate (a-KG), long chain fatty
acid (L-CFA), and f3-hydroxybutyric acid (BHBA). Each column rep-
resents mean value and brackets denote I SE.
dl) or 1-34 PTH (200 U/day, 6.2 0.2 mg/dl; 300 U/day, 6.3
0.20 mg/dl) than in normal animals (7.6 0.3 mg/dl). The blood
levels of creatinine in the PTH treated rats were not different
from the values in normal animals (0.51 0.02 mg/dl).
Table 1 and Figures 1 through 3 depict the effects of PTH on
mitochondrial oxidation of a-ketoglutarate, BHBA and LCFA,
the activity of carnitine palmitoyl transferase and on carnitine
content. The respiratory control rate of the heart mitochondria
and the ADP/0 ratios in normal rats and in PTH treated animals
were within the range of intact coupled mitochondria, and there
were no significant differences between these parameters
among the various groups of rats (Table 1). The administration
of 200 U of 1-84 PTH/day for four days produced a significant (P
<0.01) reduction in mitochondrial oxygen consumption with
a-ketoglutarate, a significant (P <0.01) impairment in LCFA
oxidation, and a significant (P <0.01) inhibition of the activity
of carnitine palmitoyl transferase. There were no significant
20
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Fig. 3. Effects of administration of 1-84 PTH (s), inactivated hormone
(U) and 1-34 PTH (200 U 11111; 300 U U) to normal (D) rats on the
activity of carnitine palmitoyl transferase of their myocardial mitochon-
dna. Each column represents mean value and brackets denote I SE.
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Fig. 4. Effects of the administration of 1-84 PTH (U) to normal (D) rats
on oxygen consumption by their myocardial mitochondria utilizing the
short chain fatty acid (S-CFA) octanoic acid. Each column represents
the mean of 5 studies and the brackets denote 1 SE,
changes in these parameters in rats treated with inactivated
PTH. Treatment with 1-84 PTH or 1-34 PTH did not cause
significant changes in the oxidation of the BHBA and carnitine
content of the heart.
The effect of 200 U of 1-84 PTH on the oxidation of SCFA
(octanoic acid) is given in Figure 4. The four day treatment with
PTH caused a significant inhibition of the oxidation of the
SCFA (normal: 158 2.3 vs. PTH: 133 1.86 nmol 02/mg
protein/mm, P < 0.01).
The nephrectomy procedure resulted in a significant (P <
0.01) rise in the serum levels of creatinine, with the values being
three times higher than normal (Table 2). There was no signif-
icant difference between the serum levels of calcium in CRF-
control and CRF-PTX rats and the values were not different
from those in normal and normal-PTX animals. The serum
levels of inorganic phosphorus were not different among the
CRF-control, CRF-PTX and normal PTX rats, but the values
were significantly lower than those in normal rats.
The effects of CRF with and without parathyroid glands and
of PTX in rats with normal renal function on a-ketoglutarate,
BHBA and LCFA oxidation and on the activity of carnitine
palmitoyl transferase and on carnitine content of heart are given
in Table 2 and Figures 5 and 6. The respiratory control rate of
the heart mitochondria and the ADP/O ratio in all groups of
animals were within the range of intact coupled mitochondna;
and there were no significant differences in these parameters
among the various groups of rats. In CRF-control animals,
oxidation of a-ketoglutarate and of palmitoyl CoA were signif-
icantly (P < 0.01) lower than that in normal rats (Fig. 5). Also
the activity of carnitine palmitoyl transferase was significantly
(P < 0.01) reduced in the CRF-control rats as compared to
normal animals (Fig. 6). Parathyroidectomy in CRF rats re-
sulted in normalization of the oxidation of a-ketoglutarate and
of palmitoyl CoA as well as the activity of carnitine palmitoyl
transferase (Figs. 5, 6). Parathyroidectomy in rats with normal
renal function had no effects on these parameters. The oxida-
tion of BHBA as well as myocardial carnitine content in
CRF-control, CRF-PTX, normal-PTX rats were not different
from those in normal animals.
Discussion
Our data demonstrate that PTH inhibits the oxidation of both
long and short chain fatty acids oxidation by heart mitochon-
dna. Since fatty acids are an important substrate utilized by the
myocardium as a major fuel for energy production, an inhibition
of their oxidation may result in impaired myocardial function.
Thus our observations demonstrate that PTH exerts another
adverse effect on myocardial metabolism in addition to those
previously reported [4].
The effect of PTH on the oxidation of LCFA by the mito-
chondria could be due to an interference in any of the steps
involved in this process. Normal oxidation of LCFA requires
adequate CoA and carnitine, normal activity of carnitine pal-
mitoyl transferase and finally intact p-oxidation sequence (Fig.
7). Since our data showed that PTH does not affect the
oxidation of BHBA by the mitochondria and since this process
requires adequate CoA, one may suggest that the inhibition of
the LCFA oxidation of PTH is not mediated through an effect
on CoA.
The effect of PTH on LCFA oxidation could also be the result
of reduced availability of carnitine and/or an effect on the
activity of carnitine palmitoyl transferase. Reduced carnitine
availability could not be the culprit. First, PTH treatment did
not cause a significant change in carnitine content of the
myocardium, and second, carnitine was added in excess during
the in vitro studies of the LCFA oxidation by the mitochondria.
It is evident, therefore, that the reduction in the activity of
carnitine palmitoyl transferase by PTH is the underlying mech-
anism through which the hormone impairs the oxidation of
LCFA. This action interfers with a key step required for the
transfer of LCFA from the intermediate space of the mitochon-
dna to their matrix.
Our finding that PTH also impaired the oxidation of the
SCFA (octanoic acid), which does not require carnitine palmi-
toyl transferase for movement through the mitochondnal ma-
trix, is consistent with an impairment in the p-oxidation se-
quenced as well (Fig. 7). It must be emphasized that the
enzymes involved in fatty acids oxidation are chain length
specific. The finding that oxidation of SCFA is impaired does
not necessarily mean that the activity of the dehydrogenases
involved in the oxidation of the LCFA are also impaired.
However, once the length of the LCFA is reduced to that of the
SCFA whose oxidation is impaired, a defect in the subsequent
oxidation steps of LCFA will become apparent.
Two observations in our study indicate that the action of PTH
on LCFA oxidation is related to the biological activity of the
hormone and not to a contaminant in the preparation. First,
inactivation of 1-84 PTH abolished its effects. Second, 1-34
PTH, which is a synthetic and pure preparation, also inhibited
LCFA oxidation and impaired the activity of carnitine palmitoyl
transferase.
It is of interest that a greater dose of 1-34 PTH was required
to exert an effect on the oxidation of LCFA and on the activity
of palmitoyl transferase. This observation is similar to data
reported on the effects of these two moieties of PTH on isolated
heart cells [I] and on myocardial bioenergetics [4]. This obser-
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Table 2. Effect of chronic renal failure with and without parathyroid glands and of parathyroidectomy in rats with normal renal function on
the oxidation of a-ketoglutarate, BHBA, and long chain fatty acids and on the activity of carnitine palmitoyl transferase of heart mitochondria
Normal
Normal CRF control CRF-PTX PTX
Serum creatinine mgldl 0.51 0.02 1.55 0.19a 1.62 O.24a 0.52 0.01
Serum calcium mg/dl 9.6 0.2 9.0 0.4 9.4 0.4 8.9 0.3
Serum phosphorus mg/dl 7.6 0.3 5.9 Ø7a 6.5 0.3a 6.1 0.3
Respiratory control ratio 10.9 0.85 11.1 0.86 11.6 1.1 9.66 0.69
ADP/O 3.0 0.04 2.8 0.06 2.7 0.04 2.8 0.04
Oxygen consumption
nmol 02/mg protein/mm
a-ketoglutarate 184 4.4 142 4.2a 178 3.2 186 3.8
f-hydroxybutyric acid 33 2.0 28 1.4 28 0.7 29 0.24
Palmitoyl Co A 68 2.9 39 1,8k 62 3.4 69 4.3
Carnitine palmitoyl
transferase
nmol/mgprotemn/mmn 19.6 1.2 14 0.81a 19 1.05 19.5 1.53
Carnitine content
nmol/,ng NCP 9.2 1.4 7.2 0.7 8.1 1.3 7.4 1.1
Data are presented as mean SE of studies in 6 rats except for carnitine contents in CRF-PTX (9 rats) and normal PTX (3 rats). Abbreviation
is: NCP, non-collagen protein.
a P < 0.01 vs. control
Fig. 5. Oxygen consumption by myocardia! mitoclzondriafro,n normal
rats (EJ), animals with chronic renal failure (, normocalcemic-
parathyroidectomized rats with CRF () and normocalcemic-parathy-
roidectomized rats with normal renal function (1111). Three substrates
were used including a-ketoglutarate (a-KG), long chain fatty acid
(L-CFA) and /3-hydroxybutyric acid (BHBA). Each column represents
mean value and brackets denote 1 SE.
Fig. 6. Carnitine palmitoyl transferase activity of myocardial mito-
chondria from normal rats (D), animals wih chronic renal failure (•),
normocalcemic-parathyroidectomized rats with CRF (D), and normo-
calcemic-parathyroidectomized rats with normal renal function (1111).
Three substrates were used including a-ketoglutarate (a-KG), long
chain fatty acid (L-CFA) and f3-hydroxybutyric acid (BHBA). Each
column represents mean value and brackets denote I SE.
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vation suggests that other parts of the intact PTH beside the
aminoterminal fragment (1-34 PTH) have biological activity, or
the intact molecule of hormone attaches more tightly to its
receptor than its aminoterminal fragment.
Chronic renal failure is associated with hyperplasia of the
parathyroid glands and elevated blood levels of PTH in man [23,
241 and dogs [25], and increased activity of the parathyroid
glands is observed within a few hours of induction of renal
failure in rats [25]. Although the blood levels of PTH were not
measured in our animals, it is reasonable to assume that a state
of secondary hyperparathyroidism did develop in the rats with
CRF and intact parathyroid glands. Our observations that the
oxidation of LCFA is inhibited and the activity of carnitine
palmitoyl transferase is impaired in CRF rats with excess PTH
indicate that CRF produces similar abnormalities to PTH treat-
ment and that the effect of CRF is mediated through the state of
secondary hyperparathyroidism. Further support for this con-
clusion is provided by the finding that normocalcemic CRF-
PTX rats had normal oxidation of LCFA and normal activity of
carnitine palmitoyl transferase. Parathyroidectomy, per se, did
not affect these processes, as demonstrated by normal oxida-
tion of fatty acids and normal activity of carnitine palmitoyl
transferase in normocalcemic PTX rats with normal renal
function. Although our data are consistent with the proposition
that the abnormalities in the oxidation of long chain fatty acids
in CRF are due to the associated secondary hyperparathyroid-
ism, other metabolic consequences of CRF may also play a
role.
The results of our study do not define the mechanism through
which PTH inhibits the activity of carnitine palmitoyl transfer-
ase or fl-oxidation sequence. It is possible that this action of the
hormone is related to its calcium ionophoric effect. Indeed PTH
has been shown to increase calcium movement into many
mammalian cells and calcium content of many tissues [26—32]
including the myocardium [4]. Previous studies have shown that
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Fig. 7. Schematic presentation of the various
steps involved in the oxidation of long and
short chain fatty acids and /3-hydroxybutyric
acid. Abbreviations are: ACS, acyl-CoA
synthetase; BHB-DH, /3-hydroxybutyrate
dehydrogenase; CPT, carnitine
palmitoyltransferase; SCAT, succinyl-C0A
acetoacetyl-CoA transferase; AcAc,
acetoacetate; BHB, /3-hydroxybutyrate; FA,
fatty acid; Cant, carnitine; CoA, coenzyme A;
AlP, adenosine triphosphate; AMP,
adenosine monophosphate; PP,
pyrophosphate; and NAD, nicotinamide
adenine dinucleotide.
the PTH-induced increase in calcium uptake by myocardium
was associated with impaired oxidation of a-ketoglutarate and
inhibition of the activity of mitochondrial creatine phosphoki-
nase and MgATPase [4]. Treatment with the calcium channel
blocker, verapamil, prevented the PTH-induced increase in
calcium uptake by myocardium and reversed the abnormalities
in mitochondrial function in PTH-treated rats [4]. Similarly, rats
with chronic renal failure displayed an increase in calcium
uptake and calcium content of the myocardium and impaired
mitochondrial function, and parathyroidectomy reversed these
effects [9]. It is reasonable, therefore, to suggest that an
increase in calcium uptake by the myocardium in rats treated
with PTH and in animals with CRF and secondary hyperpara-
thyroidism is responsible, at least in part, for the reduction in
the activity of carnitine palmitoyl transferase and impaired
oxidation of LCFA.
Our results delineate another metabolic disturbance in myo-
cardium in CRF that is mediated by the state of secondary
hyperparathyroidism. These effects of PTH on the oxidation of
long chain fatty acids, and the previously reported actions of
the hormone on myocardial energy production, shuttle and
utilization [4] provide for two pathways through which PTH
may participate in the pathogenesis of the myocardiopathy of
renal failure.
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